Search

Post-Brexit deal welcomed but leaves future relationship with EU far from settled

Rod McNeil breaks down the impact of the Brexit deal on healthcare in the UK, including medicines regulation, research funding, sharing of information and the ability to work abroad. A disorderly no-deal exit from the European Union (EU) was averted...

Ophthalmology research: lessons from the Academic Foundation Programme

The author discusses practical lessons learned during eight months of ophthalmology research as a guide for candidates considering a research themed AFP post, with general tips for anyone undertaking research whilst balancing clinical duties. Ophthalmology is already one of the...

Developing a unified approach to low-vision care

RNIB’s Preeti Singla and Louise Gow introduce the Adult Low Vision Service Quality Framework. For individuals living with visual impairment, access to high-quality low vision services can be life changing. Yet, across the UK, these services remain fragmented, with significant...

Evolving towards an interventional glaucoma mindset

Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and...

South-South collaboration for the treatment of avoidable blindness in Botswana

This article describes the value of South-South collaboration in the reduction of avoidable blindness. Specifically it describes a South-South collaboration between India and Botswana that evolved out of the VISION 2020 LINK between Cambridge University Hospitals, two institutions in India...

Imaging papilloedema vs. pseudo-papilloedema

Quite often, in the working week as an ophthalmic photographer, you will be given that patient with ‘swollen discs’ to image. These swollen discs could be a number of things, but mainly fall into one of two categories: papilloedema or...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...